MedTrace Logo

Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

NCT06489756 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-12-04

No results posted yet for this study

Summary

The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live \>2500m on pulmonary arterial pressure (PAP) assessed at 3200 m.

Conditions

  • High Altitude Pulmonary Hypertension

Interventions

OTHER

Echocardiography

Echocardiography will be performed according to clinical standards

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Talant MA Sooronbaev, Prof. Dr. · National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

  • Silvia Ulrich, Prof. Dr. · University Hospital Zurich, Department of Pulmonology

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Kyrgyzstan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06489756 on ClinicalTrials.gov